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Departments of Pathology and Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, USAAbstractBacterial zoonoses comprise a group of diseases in humans or animals acquired by direct contact with or by oral consumption of
contaminated animal materials, or via arthropod vectors. Among neglected infections, bacterial zoonoses are among the most neglected
given emerging data on incidence and prevalence as causes of acute febrile illness, even in areas where recognized neglected tropical
diseases occur frequently. Although many other bacterial infections could also be considered in this neglected category, ﬁve distinct
infections stand out because they are globally distributed, are acute febrile diseases, have high rates of morbidity and case fatality, and are
reported as commonly as malaria, typhoid or dengue virus infections in carefully designed studies in which broad-spectrum diagnoses are
actively sought. This review will focus attention on leptospirosis, relapsing fever borreliosis and rickettsioses, including scrub typhus,
murine typhus and spotted fever group rickettsiosis. Of greatest interest is the lack of distinguishing clinical features among these
infections when in humans, which confounds diagnosis where laboratory conﬁrmation is lacking, and in regions where clinical diagnosis is
often attributed to one of several perceived more common threats. As diseases such as malaria come under improved control, the real
impact of these common and under-recognized infections will become evident, as will the requirement for the strategies and allocation of
resources for their control.
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E-mail: sdumler@som.umaryland.eduIntroductionZoonoses comprise an array of infections, many known
throughout man’s history, and others that were only recently
recognized to cause human or animal disease. The phrase
‘neglected infectious disease’ recently emerged based on the
perception that neglected infections are largely tropical or
affect large poverty-ridden populations, are chronic, and are
perceived to take a steep toll on society and development [1].
However, the concept of neglected infections is neither new
nor ﬁxed, and depends on the interpretation context. Fig. 1Microbiol Infect 2015; 21: 404–415
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.04.022shows zoonoses in the USA as reported in Morbidity Mortality
Weekly Reports spanning 1981 to 2012 [2] and lacks any priority
neglected zoonosis as cited by the World Health Organization
(WHO) or the U.S. CDC [3,4]. Depending on the source,
bacterial infections deﬁned as ‘neglected’ by the Bill & Melinda
Gates Foundation include only trachoma and buruli ulcer [5],
whereas WHO and CDC add yaws and leprosy, and the list
expands to include infantile diarrhoea (enterotoxigenic Escher-
ichia coli) in the European Union [3,4,6]. The Bill & Melinda
Gates Foundation-sponsored Global Burden of Diseases, In-
juries, and Risk Factors Study 2010 list of deaths from globally
important infectious diseases includes only a small proportion
that are zoonotic (Fig. 2) [7]. The biased data presentation
occurs largely because neglected diseases cannot be compared
if they are not accurately diagnosed and reported, or assessed
based on disability-adjusted life-years if that factor is unable to
be calculated given the absence of meaningful incidence or
prevalence data. Rather the list reﬂects existing data shaped by
infections for which diagnosis or reporting is easy, or based onious Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Zoonoses reported to the CDC and published in Morbidity Mortality Weekly Reports between 1981 and 2012. Not all diseases were reportable
over this interval, and some case deﬁnitions changed. No neglected infectious disease as cited by the CDC or WHO appears on this list. Aside from
malaria, which is most often imported, the most commonly reported zoonoses in the USA over this interval were Lyme disease, spotted fever group
rickettsioses, West Nile virus infection, Anaplasma phagocytophilum infection and Ehrlichia chaffeensis infection.
CMI Chikeka and Dumler Neglected bacterial zoonoses 405evidence estimates that could be biased given the lack of such
data [8,9]. Much speculation has been made in recent years
about priorities for allocation of resources as malaria comes
under increasing control [10]. A growing number of in-
vestigations to discern the aetiology of acute febrile illness in
developed and under-resourced regions illustrate major gaps in
our knowledge, and these gaps identify a greater expanse of
neglected infectious diseases, many of which are bacterial
zoonoses [11–16]. Such investigations shed light on prevalence
estimates and the likely high human toll of inattention to other
infections, many bacterial, and the topic of this article.
Bacterial zoonoses occur with transmission via one of
several mechanisms: 1) direct contact with animals or infected
materials; 2) animal bites and scratches; 3) bites or mechanical
transmission by arthropod vectors; and 4) consumption of
contaminated foods (Table 1). The bacteria that cause the in-
fections can sometimes be acquired by more than one trans-
mission mechanism, complicating control measures. Most do
not appear on lists of neglected infections, in part because of
serious problems with deﬁnitive aetiological diagnosis and
reporting: most acute febrile illnesses in Sub-Saharan Africa are
diagnosed and reported on clinical grounds as malaria, and in
South East Asia, as typhoid fever or dengue virus infection.
When investigated objectively using pathogen-speciﬁc di-
agnostics, infections such as leptospirosis, rickettsioses and
melioidosis are diagnosed as frequently as dengue, typhoid orClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologymalaria [11–13,16,17]. Owing to the biases toward the
‘neglected diseases’ and the paucity of objective data accumu-
lated by major public health agencies, this article will focus on
only selected bacterial zoonoses for which their recognition as
important or relevant is not generally acknowledged, and for
which diagnosis, treatment and research priorities are minimal
globally. Despite the exclusion of certain bacterial zoonoses,
the approach is intended to highlight what is known and not
known as examples of why improvements in the study of these
diseases are needed.LeptospirosisLeptospirosis is a zoonosis caused by pathogenic spirochaetes
of the genus Leptospira [18–20]. Leptospires are spiral shaped,
motile aerobic spirochaetes distinguished morphologically from
other spirochaetes by characteristic hooked ends [19]. Mem-
bers of the Leptospira genus were previously grouped according
to antigenic determinants, with pathogenic leptospires
belonging to the species Leptospira interrogans and non-
pathogenic leptospires grouped under the species Leptospira
biﬂexa. A new classiﬁcation system proposes grouping of lep-
tospires by DNA relatedness into 20 species: nine pathogenic,
ﬁve of intermediate or unclear pathogenicity, and six non-
pathogenic saprophytes [21,22].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
FIG. 2. The proportional contribution of various infectious disease fatalities as reported in the Global Burden of Diseases, Injuries and Risk Factors
Study 2010 [7]. (a) Pie chart demonstrating all infectious diseases examined by the study. (b) Zoonoses occupy a minority of the reported deaths and
disease burden, and include no bacterial zoonoses.
406 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIAnimals serve as natural hosts and can be asymptomatic [19].
Leptospires are excreted in their urine, contaminating water
and soil where they can remain viable for days to months.
Rodents are the most signiﬁcant reservoirs for transmission and
when infected can shed the leptospires throughout their life-
time. Humans are accidental hosts, acquiring infection after
exposure of mucous membranes and abraded skin to animal
urine, contaminated water or soil, or infected animal tissue.
After entering the bloodstream, the spirochaetes multiply inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectorgans, most commonly the central nervous system (CNS),
kidneys and liver. They are cleared from the blood and most
tissues by the immune response but can persist and multiply in
the tubules of the kidneys.
The distribution of leptospirosis is worldwide but it occurs
with the greatest frequency in tropical and subtropical envi-
ronments [18,20]. It is estimated that more than 10 million
cases occur each year around the world and it is a signiﬁcant
cause of morbidity and mortality [21,23]. Leptospirosis is mostious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
TABLE 1. Bacterial zoonoses by transmission mechanism and causative agent(s)
Bacterial zoonoses transmitted by direct contact with animals or infected animal materials Causative agent(s)
Anthrax Bacillus anthracis
Brucellosis Brucella spp.
Cat scratch disease Bartonella spp.
Erysipelothrix infections Erysipelothrix rhusiopathiae
Glanders and melioidosis Burkholderia mallei and Burkholderia pseudomallei
Leptospirosis Leptospira interrogans spp.
Mycobacterioses Mycobacteria spp.
Q fever Coxiella burnetii
Bacterial zoonoses transmitted principally by animal bites or scratches
Pasteurellosis Pasteurella multocida and other spp.
Capnocytophaga infections Capnocytophaga canimorsus
Cat scratch disease Bartonella henselae
Rat bite fever Spirillum minus and Streptobacillus moniliformis
Vector-borne bacterial zoonoses
Lyme borreliosis Borrelia burgdorferi sensu lato (incl. Borrelia garinii, Borrelia afzelii)
Tick- and louse-borne relapsing fever borreliosis Borrelia recurrentis, Borrelia turicatae, Borrelia hermsii, others
Plague Yersinia pestis
Tularaemia Francisella tularensis
Rickettsioses Spotted fever and typhus group Rickettsia species
Ehrlichiosis and Anaplasmosis Ehrlichia chaffeensis, Anaplasma phagocytophilum
Scrub typhus Orientia tsutsugamushi




Escherichia coli O157:H7 infections Escherichia coli STEC
Yersinia enterocolitica infections Yersinia enterocolitica
Clostridium perfringens gastroenteritis Clostridium perfringens
Botulism Clostridium botulinum
Staphylococcal food poisoning Staphylococcus aureus
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sewage disposal and water treatment, yet outbreaks in
temperate regions, including the USA and Europe are well
documented [21,24]. The burden of disease is highest in the
Caribbean, Central and South America, South East Asia, Oce-
ania, India and South Asia, and Eastern Europe. The incidence in
the Seychelles in the Indian Ocean is as high as 432 per
1 000 000 population and globalization continues to occur
through international travel to these and other similar areas
where leptospirosis is endemic [25]. Although well-validated
global data on leptospirosis are lacking, the estimated global
annual incidence of leptospirosis in temperate regions is 0.1–1
cases per 100 000 population while the incidence in tropical
climates is > 10 cases per 100 000 population [26]. These are
likely underestimates because of misdiagnosis and under-
reporting, particularly in regions where other diseases with
similar non-speciﬁc presentations such as dengue and malaria
are prevalent. For example, a cross-sectional study among
hospitalized febrile patients in northeastern Malaysia between
August 2010 and February 2011 found an 8.4% seroprevalence;
but among these, only 31% were correctly diagnosed using
clinical criteria—the remainder were misdiagnosed usually as
dengue/dengue haemorrhagic fever (38%), pneumonia (14%), or
typhoid fever (7%) [27]. Among 3165 sera from acutely febrile
patients with suspected dengue in Jamaica over 2007–2008,
only 38.4% were conﬁrmed to have dengue antibodies, whereas
6% were misdiagnosed and had leptospirosis instead, and 1.6%
had serological responses consistent with both infections [28].Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyPerhaps more directly, Reller et al. showed separately in Sri
Lanka and Nicaragua where leptospirosis is often suspected,
that clinical diagnosis alone is poorly sensitive, 23% and 11%,
respectively [14,29]. Likewise, in Sri Lanka, clinical diagnosis of
other acute febrile illnesses is poor, 14% for dengue virus
infection, 3% for rickettsial infections and 0% for Chikungunya
virus infection [13,30,31].
The clinical presentation of leptospirosis is highly variable
and non-speciﬁc [21,23], explaining the poor predictive value of
clinical assessment for establishing the diagnosis as a guide to
appropriate therapy [14,29,32]. Severity ranges from subclinical
to fatal. Clinical illness usually begins abruptly after an incuba-
tion period of 2–26 days. The less severe, anicteric form of
leptospirosis resembles an inﬂuenza-like illness with fever,
rigors, myalgias, headache, abdominal pain, non-productive
cough and conjunctival suffusion, a distinguishing sign [20,21].
The severe icteric form, known as Weil’s disease, occurs in a
minority of patients and is associated with jaundice, hepatic
dysfunction, myocarditis with arrhythmias, haemorrhage, uve-
itis and multi-organ failure. Both can occur in two phases: an
acute septicaemic phase and an immune phase that can imme-
diately follow. Routine laboratory tests are typically non-
speciﬁc but can include leucocytosis with a left shift,
increased erythrocyte sedimentation rate, mildly elevated
transaminases, alkaline phosphatase and bilirubin, abnormal
urinalysis and thrombocytopenia. Leptospirosis mimics many
other tropical diseases and diagnosis requires a high degree of
clinical suspicion [14,17,33]. The average annual hospitalizationand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
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1 000 000 population and the average length of stay and hospital
charges were higher in comparison to non-leptospirosis-
associated hospitalizations [34]. In Brazil, untreated leptospi-
rosis results in signiﬁcant social costs in years of potential life
lost and partial hospitalization costs when compared with early
treatment and prevention [35]. Death occurs in 5–15% of in-
fections if untreated, and the proportion increases with age.
Acute disease is the direct result of inﬂammatory responses
to the presence of leptospires in tissues, including hepatitis and
cholestasis, interstitial nephritis, and meningoencephalitis [21].
Pulmonary haemorrhage is increasingly observed, and the
pathogenesis of this process is not deﬁned, but relates to host
immune response, the production of bacterial factors that lead
to local coagulation abnormalities, or both [18,21]. Disease re-
quires the ability of leptospires to enter organs and tissues and
spread. Leptospira genome studies show that >1% of genes are
dedicated to motility, and the presence of adhesins and invasins,
such as the outer membrane protein Loa22 and the
immunoglobulin-like LigA could contribute to this [21,36]. In
addition, genes that could affect haemostasis and coagulation are
present, including a platelet-activating factor acetylhydrolase-14
(LA2144, pafAH) and von Willebrand factor 15 type A domains
(LB054 and LB055, vwa) [21,36]. The development of dissemi-
nated intravascular coagulation with multi-organ failure provides
some evidence to support an immunological basis for severe
leptospirosis including the pro-inﬂammatory response to bac-
terial lipopolysaccharide and lipoproteins that stimulate Toll-like
receptor-2. Likewise, pulmonary haemorrhage is more frequent
in persons with high antibody titres, and there is evidence that
immunoglobulin and complement ﬁxation on host cells are
related to the expression of speciﬁc leptospiral haemostatic
proteins [36]. The late occurrence of uveitis correlates with the
‘immune’ phase and with immunoglobulin and complement
deposition [37].
Leptospirosis is diagnosed by serology, culture and molec-
ular tests [18,19,38]. Culture is deﬁnitive but slow, lacks
sensitivity, and requires specialized medium, and is therefore
not very useful for diagnostic purposes. Immunohistochemistry
has been used, but is relatively unavailable. Likewise, PCR is
sensitive but requires broad-range primers that despite the high
degree of genetic diversity, can amplify all variants. Serological
tests are used most often, particularly the reference standard,
the microscopic agglutination test. This is sensitive as early as
5–7 days after onset; a single high titre is acceptable, but
seroconversion is preferred. The pitfall of microscopic agglu-
tination test is the requirement for continued growth of mul-
tiple serovars, a daunting task for clinical laboratories, and the
delay in detection because antibodies develop later in the
course of illness.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectA recent Cochrane review was unable to discern any sig-
niﬁcant advantages to the use of antibacterial treatments for
active leptospirosis [39]. Yet many believe that antimicrobial
therapy shortens illness duration and reduces shedding of lep-
tospires in the urine [33]. Treatment options include oral
doxycycline or azithromycin for mild disease and parenteral
penicillin, doxycycline, or third-generation cephalosporin for
severe disease. Supportive care may be required for Jarisch–
Herxheimer reactions that result in a systemic inﬂammatory
response after lysis of spirochaetes with treatment.
Prevention of leptospirosis focuses on public health efforts,
chemoprophylaxis and vaccination. Public health interventions
include identiﬁcation and modiﬁcation of risk factors through
public education. Human and animal behavioural and environ-
mental risk factors vary by region and include rodent in-
festations, particularly rats, exposure to contaminated surface
water such as in rice paddies, and the presence of skin wounds.
A recent study by Samarakoon and Gunawardena indicates that
in endemic regions the knowledge of leptospirosis prevention
is adequate but does not lead to implementation of personal
protective measures [40]. Prophylaxis with doxycycline
(200 mg once a week) reduces morbidity and mortality during
outbreaks and other homeoprophylactic measures are re-
ported to provide preventive beneﬁt, but will require exten-
sive evaluation [41,42]. There is no human vaccine available but
vaccines do exist for animal reservoirs including dogs and
cattle.Relapsing fever borreliosisRelapsing fever is an arthropod-borne disease caused by path-
ogenic spirochaetes of the genus Borrelia [43,44]. It occurs in
two major forms: tick-borne relapsing fever (TBRF) and louse-
borne relapsing fever (LBRF). LBRF is primarily seen in East and
Central Africa and is a frequent cause of epidemics in areas of
extreme poverty, war, natural disasters and overcrowding. It is
widely perceived that there has been a decline in the incidence
of LBRF secondary to improved standards of living and the
introduction of the insecticide DDT. However, LBRF is still a
major public health issue in East Africa, particularly in Ethiopia
and in surrounding regions where louse infestation is
commonplace. TBRF is found worldwide and is endemic in
many countries including the Americas, Central Asia, the
Mediterranean region and many parts of Africa. In most rural
areas of Senegal, Mauritania and Mali, TBRF is a common cause
of fever with incidence comparable to Plasmodium falciparum
malaria and inﬂuenza [45]. The incidence of tick-borne relapsing
fever peaks in summer but infection can occur year round,
depending on local climate conditions.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
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Borreliae are thin, helical, motile spirochaetes that are unique in
their ability to change their outer membrane surface proteins
by gene conversion to generate antigenic variation [43]. Each
relapse is associated with the emergence of a unique antigenic
bacterial clone that is subsequently controlled by the immune
system, only to select for new antigenic variant clones and
another relapse of fever and disease. In fact, some variant
clones have a propensity for dissemination into tissues and
organs such as the CNS.
Louse-borne relapsing fever is caused by Borrelia recurrentis,
now believed to be a reduced-genome variant of the TBRF
Borrelia duttonii [46]. The vector for LBRF is the human body
louse (Pediculus humanus), so humans are the only known
reservoir for this spirochaete [44]. TBRF is transmitted to
humans through the bite of infected soft ticks of the genus
Ornithodoros. There are many Borrelia species that cause TBRF,
roughly divided into Old World and New World species, and
they are associated with speciﬁc tick species. Unlike the human
body louse that lives for several weeks, Ornithodoros ticks can
live for many years between blood meals, harbour spirochaetes
for prolonged periods, and can transmit the pathogen vertically
to offspring [44].
Lice acquire the spirochaetes by feeding on infected humans
whereas humans acquire LBRF by scratching infected haemo-
lymph of a crushed louse into the skin [44,47]. Ticks become
infected by feeding on infected wild rodents and then transmit
the spirochaetes to humans through a tick bite. After entering
the blood, the spirochaetes disseminate, seeding multiple or-
gans including the CNS in the case of TBRF.
Relapsing fever is characterized by two or more episodes of
high fever (usually >39°C), myalgias, arthralgias, nausea, vom-
iting, headache and non-productive cough [48,49]. Signs can
include haemodynamic instability, rash, abdominal tenderness
and bleeding. Laboratory studies can reveal mild elevations in
bilirubin and aminotransferases, thrombocytopenia and
anaemia. Later in the illness, jaundice, hepatosplenomegaly and
myocarditis can occur [50]. The initial febrile episode typically
lasts 3–6 days and is followed by an afebrile period of
4–14 days, after which fever and symptoms recur. Subsequent
relapses are usually less severe and can follow at 1- to 2-week
intervals.
Because the WHO advises a presumptive diagnosis of ma-
laria in endemic regions, or collects ‘verbal autopsy’ reports for
deaths, relapsing fever often goes undetected, particularly in
parts of Africa where malaria is highly prevalent. A study by
Nordstrand et al. in Togo, West Africa between 2002 and 2004
found that among febrile patients originally diagnosed and
treated for malaria, the prevalence of TBRF was 8.8%,
compared with 63.1% for malaria; 4.5% of patients had bothClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologymalaria and TBRF [51]. Similarly, among a cohort of individuals
participating in a study of mass treatment to eradicate trachoma
in Tanzania, 17% of febrile episodes were caused by either
Plasmodium falciparum or Plasmodium vivax, whereas 4% were
attributed to relapsing fever [52], underscoring how uncor-
roborated clinical diagnosis can lead to erroneous reporting
coupled with inﬂation of the incidence of reportable infections
at the expense of other aetiologies.
Although the incidence of relapsing fever has declined in the
developed world, it continues to be a formidable public health
issue in certain regions. In Tanzania, for example, infection with
TBRF is associated with signiﬁcant morbidity and mortality,
especially in women and children, where it results in high
perinatal mortality (436/1000 births) and is frequently listed as
one of the top ten causes of mortality in children under 5 years
of age [53,54]. A retrospective study conducted between 2009
and 2012 of patients with LBRF-like symptoms who were
admitted to a referral hospital in Ethiopia found the prevalence
to be 4.9% and case fatality rates ranged from 2 to 6% [55].
Relapsing fever can account for up to 27% of hospitalizations in
some regions [56]. There still exists the possibility of signiﬁcant
re-emergence, particularly as travel patterns continue to
change and imported cases of relapsing fever are described.
There is also evidence of a resurgence of louse infestation
among certain groups. In Marseille, France, Brouqui et al. found
a high prevalence of louse-borne infections in the homeless and
a high level of exposure to tick-borne diseases [57].
Relapsing fever is diagnosed by visualization of spirochaetes
in the blood using dark-ﬁeld microscopy or Wright or Giemsa
staining on thin and thick blood smears [49]. Serological tests
were typically unreliable, but have improved with the devel-
opment of assays based on detection of antibodies to relapsing
fever spirochaete-speciﬁc GlpQ [58]. Culture requires tech-
niques that are not available in most laboratories. Nucleic acid
ampliﬁcation tests are available in some public health facilities,
but not generally accessible to primary healthcare workers, or
accessible in under-resourced regions where relapsing fever is
often present.
Few careful studies of in vitro susceptibility for relapsing fever
Borrelia species are published to guide treatment. LBRF was
shown to be effectively treated with a single dose of oral
tetracycline or doxycycline, or intramuscular penicillin G pro-
caine [43,49], but over one-third of patients had recurrent fe-
ver, suggesting that a prolonged regimen is preferable. Similarly,
the relapse rate of TBRF is at least 20% after single-dose
therapy; hence, the treatment for TBRF is extended to
7–10 days. Relapses yield as many as 108 bacteria/mL of blood,
so antibiotic therapy can trigger a Jarisch–Herxheimer reac-
tion, particularly with LBRF, and its occurrence is associated
with high mortality. Tetracyclines are highly effective at clearingand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
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with more frequent and severe episodes of Jarisch–
Herxheimer reactions [59,60]. Therefore, preferred treatment
employs either single-dose doxycycline or tetracycline, or a
single dose of procaine penicillin intramuscularly followed by 2
or more days of oral doxycycline or tetracycline. Prevention of
infection requires good personal hygiene, delousing, laundering
at high temperatures and application of insecticides to clothing
and bedding to diminish louse infestations for LBRF. TBRF
prevention includes exclusion of rodents that host the argasid
tick vectors, avoiding habitats that harbour the ticks them-
selves, and the use of tick repellents.Scrub typhus, murine typhus and spotted
fever rickettsiosisBacteria in the genera Orientia, Rickettsia, Ehrlichia and Ana-
plasma are obligate intracellular α2 proteobacteria in the Order
Rickettsiales and Families Rickettsiaceae and Anaplasmataceae
[61]. Genome sequences illustrate that these agents adapted to
an obligatory intracellular lifestyle through the loss of genes and
pathways required for extracellular growth [62]. Regardless,
each contains DNA, RNA, ribosomes, divides by binary ﬁssion
and possesses a cell wall with ultrastructural characteristics of
Gram-negative bacteria. Rickettsiaceae members (Rickettsia and
Orientia) target endothelial cells in mammals and reside within
the cytosol. In contrast, Anaplasmataceae family members
usually reside in haematopoietic-derived cells, such as leuco-
cytes in mammals where they propagate within pathogen-
modiﬁed endosomes. All Rickettsiales have at least part of
their life cycle in vectors, and for Rickettsia, Orientia, Ehrlichia
and Anaplasma these are usually arthropods, often ticks, ﬂeas,
lice or mites.
The genus Rickettsia is divided into spotted fever (SFGR) and
typhus groups. Genome studies illustrate diversity with SFGR,
yet these cluster separately from typhus group rickettsiae [62].
Several species occupy intermediate positions sometimes called
‘transitional’ or ‘ancestral’. There are over 25 recognized SFGR
species and two typhus group species; most are human path-
ogens, yet at least several ‘transitional’ and ‘ancestral’ rickettsiae
are questionably pathogenic or never associated with known
human or animal disease. The genus Orientia has a similar de-
gree of genetic diversity as for SFGR, yet has only two named
species, Orientia tsutsugamushi and Orientia chuto, both human
pathogens. Although many Anaplasmataceae are animal patho-
gens, only a limited range are human pathogens.
Among the rickettsial agents, the most neglected for which
sufﬁcient evidence exists that there are large global disease
burdens include O. tsutsugamushi, the agent of scrub typhusClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect[10,12,13,16], Rickettsia typhi, the aetiological agent of murine
typhus [11–13], and various SFGR, especially Rickettsia rickettsii
(Rocky Mountain spotted fever [RMSF]) [63,64], Rickettsia con-
orii (Mediterranean spotted fever), Rickettsia africae (African tick
bite fever), and likely others in Asia and Australia (Rickettsia
sibirica, Rickettsia heilongjiangensis, Rickettsia japonica, Rickettsia
honei and Rickettsia australis) [65,66]. Although the emergence
of ehrlichiosis and anaplasmosis argues for their importance as
globally neglected infections [67], for simplicity, only scrub ty-
phus, murine typhus and ‘generic’ SFGR will be considered
here.Scrub typhusOrientia tsutsugamushi is transmitted by larval trombiculid mites
(genus Leptotrombidium), which are distributed throughout Asia
and parts of Australia. The range of scrub typhus extends from
northeast Asia to Papua/New Guinea and Northern Australia in
the southeast, the Maldives and Réunion Islands in the south-
west and to Pakistan and Afghanistan in the northwest [68].
This distribution encompasses regions where over 2 billion
people live. Several recent studies provide preliminary evidence
that scrub typhus could be endemic outside the previously
established ranges, and extend into Africa and as far as South
America, although much more study is needed [10,69,70].
Based on the wide ecological distribution of the pathogen, the
density of populations in these geographic regions and the high
seroprevalence and incidence of infection, it is conservatively
estimated that there are more than 1 million cases of scrub
typhus yearly [10].
Scrub typhus usually presents as undifferentiated fever
[68,71]. Patients also often demonstrate headache, myalgias,
rash, among other manifestations, and an eschar at the site of
the mite bite is a key sign (Table 2). Laboratory studies are
usually not revealing, except for a normal leucocyte count and
left shift with thrombocytopenia, and moderate increases in
serum hepatic transaminase activities (Table 2), all common
features of infections described here. The diagnosis of scrub
typhus relies on clinical suspicion for early treatment [72].
Diagnostic approaches during acute disease include immuno-
histochemical demonstration of O. tsutsugamushi in eschar bi-
opsies, and although much less sensitive, PCR ampliﬁcation of
O. tsutsugamushi-speciﬁc nucleic acids from blood [72,73].
Serology is most often employed and includes speciﬁc indirect
immunoﬂuorescence assays for O. tsutsugamushi IgG and IgM,
although the latter is associated with false positive tests in the
absence of a concurrent IgG seroconversion [60,74]. Point-of-
care assays are not readily available or well validated. Patients
with scrub typhus are best treated with doxycycline, andious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
TABLE 2. Clinical signs, symptoms and laboratory ﬁndings of neglected bacterial zoonoses compared with dengue virus infection
(% of cases with ﬁnding)








(R. typhi) Dengue virus infection
Clinical ﬁndings
Fever 100 100 100 99 100
Headache 85 100 91 59 78
Myalgia 77 32 72 46 77
Rash 5 49a 90 37 11-53
Rash on palms and soles na nab 82 na na
Nausea or vomiting 45 28 60 40 53
Abdominal pain 33 na 43 17 na
Conjunctivitis 61 29 30 na na
Pneumonitis 37 28 15 15 35
Any severe neurological complication <25 10 26 6 1-6
Laboratory ﬁndings
Leucocytosis (white blood cell count) > 10 × 109/L 39 34 28 22 6
Leucopenia (white blood cells) < 5 × 109/L 8 3 24 13 25
Platelet count <150 × 109/L 26 25 44 46 59
Elevated ALT or AST 78 70 50 57 64
aIncludes eschars.
bna, data not available.
CMI Chikeka and Dumler Neglected bacterial zoonoses 411although questions about doxycycline resistance in some Thai
strains are not resolved, azithromycin seems to be an effective
alternative [75]. Severe outcomes include pneumonia, renal
failure, meningoencephalitis, shock, gastrointestinal bleeding,
myocarditis and death [76].
In some Asia-Paciﬁc regions, scrub typhus can account for up
to 23% of all febrile illness in hospitalized patients [77]. A study
by Chanyasanha et al. of febrile patients in Thailand who pre-
sented to malaria clinics found the seroprevalence of scrub
typhus to be close to 60% [78]. A meta-analysis using the search
terms ‘scrub typhus incidence’ identiﬁed 132 publications that
examined acutely febrile subjects between 2009 and 2015, for
which 23 contained sufﬁcient details of study design, patient
enrolment, diagnostic approach, and individualized data to
discern incidence and prevalence (see Supplementary material,
Table S1). All studies were conducted in Asia (Lao PDR,
Thailand, Vietnam, China, India, Sri Lanka, Indonesia, Bangladesh
and Malaysia). This analysis accumulated data from 10 192
subjects with acute febrile illness, and identiﬁed 1881 incident
scrub typhus infections, for a median of 14% (interquartile
range 8–31%) infection rate. One recent study by Varghese
et al. conducted between 2005 and 2010 on patients with scrub
typhus in South India found the overall case fatality rate to be
9% with shock, renal failure and CNS involvement associated
with a higher mortality [79]. The case fatality rate varies in
contemporary studies from 0.5% to 24% [80] to historical highs
between 30 and 50% [81], such that the mortality among 1
million infections in a single year is probably enormous.
Scrub typhus remains a serious public health issue. In regions
such as India, Sri Lanka and China where it was thought to have
declined, scrub typhus has experienced a resurgence, and it is
increasingly identiﬁed as an emerging infection in new foci [10].
It is unclear whether this is the result of improved diagnosticClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologymethods and increased awareness, expansion of farmlands and
population growth, or changes in travel and migration patterns.
Misdiagnosis and under-diagnosis are also known to occur
through the lack of availability of diagnostic tests and the non-
speciﬁc nature of symptoms, especially when the character-
istic eschar is not present. The economic impact of scrub ty-
phus has only recently begun to be explored in regions of China
where the disease has rapidly re-emerged in recent years [82].Murine typhus and spotted fever rickettsiosisMurine typhus occurs when the rat ﬂea (Xenopsylla cheopis) or
the cat ﬂea (Ctenocephalides felis) transmits R. typhi via infected
ﬂea faeces into the ﬂea bite wound [83]. The apparent obliga-
tory relationship of rats or domestic pets that harbour ﬂeas
with human domiciles makes murine typhus a risk in any
location with human activities, and especially in regions with
warm weather and year-round ﬂea activity. Murine typhus has
been reported on every continent (except Antarctica), and is a
particular risk in tropical regions of South East Asia, Africa,
Central and South America, and even in southern parts of the
USA and Europe. Well-established prevalence data are lacking
in almost all regions owing to neglect of this disease, yet
seroprevalence studies continue to demonstrate high rates in
many locations and have implicated murine typhus as the
causative agent in increasingly large proportions of patients with
febrile illness. Hamaguchi et al. [97] studied acute undifferenti-
ated fever in hospitalized patients in Northern Vietnam, where
33% were seropositive for R. typhi. Certain communities,
notably, homeless populations, have higher seroprevalence
rates, ranging from 9.6% in the USA to 22% in Marseille, France,
and to 67% in Bangladesh [84] and 21% in Lao PDR [85]. A pilotand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
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typhus + incidence’, ‘murine typhus + acute febrile illness’, and
‘murine typhus’ retrieved 880 articles since 1934 and only the
325 articles dating to 2001 were reviewed for adequacy of
details and methodology, including geographic location for in-
clusion in the study, and with sole focus on studies of incidence
among prospective acute febrile disease studies (see Supple-
mentary material, Table S2). Selected studies originated from
every continent except Antarctica. Of the 325 articles
reviewed, 26 were selected for inclusion, comprising a total of
8642 patients, among which 1486 (17.2%) were deemed to
have murine typhus based on serology and PCR and culture.
The median proportion of murine typhus cases among the
studies was 7.9% (interquartile range 4.2–14.5%).
As with scrub typhus, the clinical presentation is most often
undifferentiated fever, but lacking an eschar (Table 2) [86–88].
A rash can develop in half of infected patients. Complications
are similar to those of other rickettsioses. The case fatality rate
is variably between 0.5 and 4% in contemporary series and
most infections have a benign clinical course; however,
morbidity can be signiﬁcant particularly in cases of delayed
diagnosis and in the elderly who, even with proper treatment,
suffer a greater number of complications.
Spotted fever group rickettsiosis is best known because of
the severity of RMSF (R. rickettsii infection) [89–91]. Whereas
RMSF occurs only in the western hemisphere, other SFGR
occur globally. Individual species vary in pathogenicity, but the
underlying pathology for SFGR is endothelial cell infection,
vasculitis and increased systemic and pulmonary vascular
permeability [92]. The majority of SFGR are transmitted by tick
bites; for R. rickettsii this includes Dermacentor variabilis, Der-
macentor andersoni and Rhipicephalus sanguineus in North
America, and Amblyomma species in Central and South Amer-
ica. Rickettsia conorii is vectored by Rhipicephalus sanguineus in
the Mediterranean region, whereas R. africae is transmitted via
Amblyomma tick bites in Sub-Saharan Africa. A few SFGR are
vectored by other arthropods (mites for rickettsial pox (Rick-
ettsia akari); ﬂeas for cat ﬂea typhus (Rickettsia felis)).
Spotted fever group rickettsioses are among the most viru-
lent of all human infections, especially RMSF for which historical
case fatality rates of 25–80% are recorded [92]. Contemporary
data describe case fatality rates between 0.5 and 8–12% in the
USA and up to 35% in Brazil. In Beja, Portugal in 1997, the case
fatality rate in hospitalized patients with Mediterranean spotted
fever was 32.3% and in the USA, the American Indian popula-
tion is especially affected by RMSF with both incidence and case
fatality rates signiﬁcantly higher than that of other racial groups;
this incidence continues to increase at a disproportionate rate.
Of particular interest is the high seroprevalence of SFGR in
many regions around the world where human SFGR are notClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectknown to exist [91,93]. In southern Taiwan, a region where
spotted fever is poorly characterized, an investigation of 413
febrile patients found that 49 (11.9%) were seropositive for
spotted fever group rickettsiae. Spotted fever is also increas-
ingly diagnosed in South Asia, including Sri Lanka where spotted
fever rickettsiosis occurred in 10% of febrile patients, second in
number only to leptospirosis [13], and the seroprevalence was
33% for any rickettsial infection. Despite inadequate data
collection, reported cases of SFGR are at historical highs in the
USA and globally [64,91]. The reasons for this are not clear, but
could include greater clinical suspicion, case deﬁnition and
diagnostic test changes, or real increases in disease incidence
and prevalence. The latter is in part likely given the increasingly
deﬁned distribution of infected vectors [91].
Clinical manifestations of RMSF and other SFGR include
fever, and variably headache, myalgias, rash, (macular, mac-
ulopapular or petechial), abdominal pain, nausea, vomiting,
diarrhoea, and in severe cases, renal failure, non-cardiogenic
pulmonary oedema, shock and multi-organ failure, and CNS
involvement (meningoencephalitis, cerebral oedema, hernia-
tion) (Table 2). Most SFGR do not demonstrate this degree of
severity, but it is possible in any single case. Many patients have
eschars (except in RMSF), and some develop vesicular rashes.
Major factors for ineffective diagnosis and delayed therapy
include absence of a typical rash, presentation during non-peak
tick activity season, and presentation during ﬁrst 3 days of
illness when a rash may not be present [94].
Murine typhus and SFGR diagnosis requires clinical suspicion
because adequate diagnostic tests in the acute phase of disease
are not available [95]. If rash is present, rickettsiae can be
demonstrated by immunohistochemistry in rash lesion biopsies
in SFGR and murine typhus. Although PCR sensitivity in blood
is low (<25%), accumulating data suggest that skin biopsy PCR
could be sensitive [91]. The most sensitive diagnostic test,
immunoﬂuorescence assay, is only conﬁrmatory because it
requires acute and convalescent serum antibody titres. How-
ever, in general, immunoﬂuorescence assays cannot distinguish
SFGR species or cross-reactions with typhus group rickettsiae.
Cultivation is not timely and is generally considered dangerous
and unacceptable for clinical laboratories. Perhaps most chal-
lenging of all is the fact that serodiagnosis only works well with
paired sera separated by at least 14 days, precluding its use for
diagnosis and management at the time of active infection. Given
the marked but mostly unrecognized incidence of these in-
fections worldwide, and their high case fatality rates, readily
available accurate and sensitive point-of-care diagnostic devices
are desperately needed.
Both SFGR and murine typhus are treated with doxycycline;
however, in a study that examined treatment practices in the
USA, fewer than 40% of healthcare providers correctly choseious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 404–415
CMI Chikeka and Dumler Neglected bacterial zoonoses 413doxycycline as the treatment of choice for RMSF for children
<8 years of age, a potential cause of the increased case fatality
rates in this age category [95]. Controlled clinical trials have not
been conducted to adequately deﬁne efﬁcacy among antibiotics
except for R. conorii but some evidence exists to support the
use of ﬂuoroquinolones for murine typhus and forms of SFGR
other than RMSF, though their use has become controversial
[96]. Currently, no vaccines exist for spotted fever rickettsiosis,
murine typhus or scrub typhus. Prevention requires avoidance
of bites by ticks, ﬂeas and chiggers by avoiding infested loca-
tions, by wearing clothing that potentially excludes their ability
to access the skin, or by use of repellents. Prophylactic anti-
biotic treatment is not well assessed and currently cannot be
advocated.
ConclusionsOther than leptospirosis, relapsing fever, scrub typhus and
rickettsioses are not yet recognized as neglected diseases by the
WHO, despite data that illustrate their high incidence and
prevalence and the potentially dramatic morbidity and costs to
human life. Future goals should include establishing their inci-
dence and prevalence comparative to other infections that
seemingly occur at similar rates. Development of easily
deployed point-of-care diagnostics will be critical to assist in
accurately collecting these data and in directing appropriate
care and treatments. Careful clinical and epidemiological/
ecological studies, including the roles of animal or vector res-
ervoirs that increase risk will identify opportunities to prevent
infection. Study of human infections could identify new loca-
tions where other preventative methods, including vaccination
might be used. A basic analysis of disability-adjusted life-years
will depend on careful collection of such data and could drive
deployment of critically short resources in areas where these
infections cause more harm than others commonly believed to
have the greatest impact on humans and their environments.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
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